Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT07240935
Recruiting Not applicable

Spanish Validation of a Psychosocial Needs Assessment for Adolescents and Young Adults With Cancer (AYA-POST)

NCT07240935 · tracked via the Priya Life Science Spain tracker
Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Phase
Not applicable
Started
2025-10-10
Last updated
2026-01-21

Condition(s) studied

AYA Cancer Patients

Investigational drug(s) / intervention(s)

AYA-POST questionaries

AYA-POST questionaries: AYA-POST questionaries includes: Distress Thermometer and psychosocial needs assesment

Study summary

This prospective multicenter study aims to validate the Spanish version of the Distress Thermometer and accompanying list of psychosocial needs specifically adapted for adolescents and young adults (AYA) aged 15 to 25 who are diagnosed with cancer.

These tools, firstly developed by the National Comprehensive Cancer Network (NCCN) and then specifically adapted for AYA by Canteen Australia and validated in English-speaking countries, are widely used around the world to quickly identify emotional distress and unmet practical or social needs in cancer patients, helpting to detect their emotional distress and support needs, which can differ significantly from those of children or older adults.

By validating these screening tools in Spanish this study seeks to confirm whether they can reliably identify young patients who may be experiencing psychosocial difficulties.

Once validated, these tools can be easily integrated into clinical practice in Spanish-speaking countries, helping healthcare teams quickly identify vulnerable young patients, respond to their emotional needs earlier, and improve the overall quality of care.

The results will also highlight which psychosocial needs are most common in AYA cancer patients, supporting the development of future programs and services tailored to this population.

Eligibility

Sex
ALL
Min age
15 Years
Max age
25 Years
Healthy volunteers
No
Inclusion Criteria: * Patients between 15 and 25 years old who provide informed consent (\> 18 yo) or parents informed consent and patient consent in case of minors (15 to 18 yo) * Diagnosis of cancer (malignant solid tumor or hematologic malignancy) within 6 months prior to study inclusion or whose first non-surgical treatment (chemotherapy, radiotherapy, or targeted therapy) started within the last 6 months. * Treated from diagnosis or first non-surgical treatment at centers where the study is open. Exclusion Criteria: * Patients who are not receiving their first line of non-surgical treatment. * Patients who do not have good understanding of Spanish (language used for the screening tool and questionnaires). * Patients with severe neurological impairment or other conditions that, in the investigator's opinion, prevent proper completion of study procedures.

Primary outcome measure(s)

  • Validation of the Spanish version of AYA-POST — From enrollment to the end of follow-up 1 year after finishing cancer treatment
    Correlation between the Spanish AYA-POST and currently validated HADS

Trial sites (1)

FacilityCityRegionStatus
Hospital Vall Hebron Barcelona Barcelona Recruiting

More Hospital Universitari Vall d'Hebron Research Institute trials in Spain

Integrative Diagnosis for SCD and Other RADs Recruiting
Immunological Reset to Allow Access to HLA Compatible Transplantation in Highly Sensitized Kidney Transplant Candidates Through Non-myeloablative Autologous Stemm Cell Transplantation Recruiting
Migraine and Endometriosis: The FEMININE Study Starting soon
Accelerating Referral for Thrombectomy in Acute Stroke Patients Using an Artificial Intelligence-based Software Recruiting
Smartwatch and External Holter Monitoring to Detect Atrial Fibrillation in Patients With Cryptogenic Stroke Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07240935 on ClinicalTrials.gov ↗ ← All trials in Spain